- Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform Business Wire
- Kite sails into in vivo CAR-T space via $350M Interius buyout Fierce Biotech
- Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million statnews.com
- Gilead Sciences to Buy Interius BioTherapeutics for $350 Million MarketScreener
- Gilead’s Kite buying Interius BioTherapeutics for $350M Seeking Alpha
Source link
